Hypogonadism Completed Phase 3 Trials for Alendronic acid (DB00630)

IndicationStatusPhase
DBCOND0009256 (Hypogonadism)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00048841Prevention of Osteoporosis in Men With Prostate CancerPrevention